IL256322B - Improved formulations of deferasirox and methods of making the same - Google Patents
Improved formulations of deferasirox and methods of making the sameInfo
- Publication number
- IL256322B IL256322B IL256322A IL25632217A IL256322B IL 256322 B IL256322 B IL 256322B IL 256322 A IL256322 A IL 256322A IL 25632217 A IL25632217 A IL 25632217A IL 256322 B IL256322 B IL 256322B
- Authority
- IL
- Israel
- Prior art keywords
- deprasirox
- manufacture
- methods
- improved formulations
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180998P | 2015-06-17 | 2015-06-17 | |
| PCT/US2016/038089 WO2016205658A1 (en) | 2015-06-17 | 2016-06-17 | Improved formulations of deferasirox and methods of making the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL256322A IL256322A (en) | 2018-02-28 |
| IL256322B true IL256322B (en) | 2022-03-01 |
Family
ID=57546755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL256322A IL256322B (en) | 2015-06-17 | 2017-12-14 | Improved formulations of deferasirox and methods of making the same |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10265301B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3310354A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018517734A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107847490A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016280280B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2989145C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1254608A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL256322B (cg-RX-API-DMAC7.html) |
| MA (1) | MA43271A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016205658A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103290106B (zh) | 2007-12-05 | 2015-07-29 | 考利达基因组股份有限公司 | 测序反应中碱基的有效确定 |
| US10098857B2 (en) | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
| EP2977455B1 (en) | 2009-06-15 | 2020-04-15 | Complete Genomics, Inc. | Method for long fragment read sequencing |
| US10837879B2 (en) | 2011-11-02 | 2020-11-17 | Complete Genomics, Inc. | Treatment for stabilizing nucleic acid arrays |
| CZ2017255A3 (cs) * | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
| WO2019055490A1 (en) | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION |
| EP3706731A4 (en) * | 2017-11-10 | 2021-08-18 | Dispersol Technologies, LLC | IMPROVED DRUG FORMULATIONS |
| CA3113175A1 (en) * | 2018-09-20 | 2020-03-26 | Tautona Group Ip Holding Company, L.L.C. | Iron chelating compounds for treating aesthetic skin conditions |
| AU2021212258A1 (en) | 2020-01-31 | 2022-09-29 | Flex Pharma, Llc | Amorphous nilotinib microparticles and uses thereof |
| EP4142699A1 (en) | 2020-04-30 | 2023-03-08 | Nanocopoeia LLC | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| CN112870361A (zh) * | 2021-01-28 | 2021-06-01 | 重庆医科大学 | 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用 |
| CN116203161A (zh) * | 2022-05-30 | 2023-06-02 | 上海奥科达医药科技股份有限公司 | 地拉罗司颗粒剂中相关杂质的检测方法 |
| WO2025151876A1 (en) * | 2024-01-11 | 2025-07-17 | Minneamrita Therapeutics Llc | Triptolide formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| AU2006303514B2 (en) * | 2005-10-19 | 2010-06-24 | Novartis Ag | Dispersible tablets comprising deferasirox |
| CA3076115C (en) | 2007-08-21 | 2022-06-28 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| WO2009067557A1 (en) * | 2007-11-19 | 2009-05-28 | Teva Pharmaceutical Industries Ltd. | Deferasirox pharmaceutical compositions |
| EP2291360A2 (en) * | 2008-04-21 | 2011-03-09 | Actavis Group PTC ehf. | Solid state forms of deferasirox salts and process for the preparation thereof |
| BR112012013710A2 (pt) * | 2009-12-07 | 2015-09-15 | Mapi Pharma Ltd | processos para a preparação de deferasirox e polimorfos de deferasirox. |
| EP2929877A1 (en) * | 2010-07-08 | 2015-10-14 | ratiopharm GmbH | Oral dosage form of deferasirox |
| EP2632907B1 (en) * | 2010-08-25 | 2015-10-14 | Davuluri, Ramamohan Rao | Process for preparing 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparing deferasirox |
| MX2013003522A (es) * | 2010-10-01 | 2013-05-22 | Cipla Ltd | Composicion farmaceutica. |
| WO2012116238A1 (en) * | 2011-02-23 | 2012-08-30 | Dispersol Technologies, Llc | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS |
| TWI686215B (zh) * | 2013-03-08 | 2020-03-01 | 瑞士商諾華公司 | 祛鐵斯若(deferasirox)之口服配方 |
| CA2911671A1 (en) | 2013-05-10 | 2014-11-13 | Cipla Limited | Low dose pharmaceutical composition |
-
2016
- 2016-06-17 WO PCT/US2016/038089 patent/WO2016205658A1/en not_active Ceased
- 2016-06-17 JP JP2017565048A patent/JP2018517734A/ja active Pending
- 2016-06-17 MA MA043271A patent/MA43271A/fr unknown
- 2016-06-17 CN CN201680042313.0A patent/CN107847490A/zh active Pending
- 2016-06-17 CA CA2989145A patent/CA2989145C/en active Active
- 2016-06-17 AU AU2016280280A patent/AU2016280280B2/en active Active
- 2016-06-17 EP EP16812529.2A patent/EP3310354A4/en active Pending
- 2016-06-17 HK HK18113574.7A patent/HK1254608A1/zh unknown
- 2016-06-17 US US15/185,888 patent/US10265301B2/en active Active
-
2017
- 2017-06-28 US US15/636,174 patent/US10258608B2/en active Active
- 2017-12-14 IL IL256322A patent/IL256322B/en unknown
-
2019
- 2019-02-06 US US16/268,785 patent/US11878005B2/en active Active
-
2021
- 2021-12-02 AU AU2021277731A patent/AU2021277731B2/en active Active
-
2023
- 2023-11-24 US US18/518,819 patent/US20240091201A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2989145C (en) | 2024-10-29 |
| MA43271A (fr) | 2018-09-26 |
| EP3310354A4 (en) | 2018-12-12 |
| CN107847490A (zh) | 2018-03-27 |
| EP3310354A1 (en) | 2018-04-25 |
| IL256322A (en) | 2018-02-28 |
| US10258608B2 (en) | 2019-04-16 |
| AU2021277731A1 (en) | 2021-12-23 |
| AU2016280280A1 (en) | 2018-01-04 |
| HK1254608A1 (zh) | 2019-07-26 |
| US20240091201A1 (en) | 2024-03-21 |
| US20170027911A1 (en) | 2017-02-02 |
| US10265301B2 (en) | 2019-04-23 |
| US11878005B2 (en) | 2024-01-23 |
| AU2024202528A1 (en) | 2024-05-09 |
| WO2016205658A1 (en) | 2016-12-22 |
| AU2016280280B2 (en) | 2021-09-02 |
| US20190167643A1 (en) | 2019-06-06 |
| CA2989145A1 (en) | 2016-12-22 |
| US20170296514A1 (en) | 2017-10-19 |
| JP2018517734A (ja) | 2018-07-05 |
| AU2021277731B2 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256322B (en) | Improved formulations of deferasirox and methods of making the same | |
| IL258931A (en) | Therapeutic compounds and methods | |
| HUE046756T2 (hu) | Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei | |
| PL3445850T3 (pl) | Sposoby otrzymywania jednoniciowego rna | |
| PT3142637T (pt) | Formulações e métodos de tratamento de queratina | |
| PL3353210T3 (pl) | Przeciwciała anty-TIGIT i sposoby stosowania | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| BR112018000129A2 (pt) | oxiesteróis e seus métodos de utilização | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| PL3325443T3 (pl) | Sposób otrzymywania pridopidyny | |
| PL3371206T3 (pl) | Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka | |
| DK3185853T3 (da) | Inhalerbare pulverformuleringer af alginatoligomerer | |
| LT3341027T (lt) | Transfekcijos kompleksai ir jų panaudojimo būdai | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| IL255307B (en) | Tpp1 formulations and uses thereon in cln2 disease | |
| SI3800177T1 (sl) | Sestavki fenfluramina in njihovi načini priprave | |
| MA43134A (fr) | Compositions et méthodes de transduction tumorale | |
| IL272851A (en) | Methods of using dipivefrin | |
| DK3283210T3 (da) | Fremgangsmåde | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
| DK3374495T3 (da) | Forbedrede fremgangsmåder til vævsfremstilling |